RENXF (Renalytix) Other Stockholders Equity: $16.60 Mil (As of Dec. 2025)


What is Renalytix Other Stockholders Equity?

Renalytix RENXF Other Stockholders Equity is $16.60 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

Renalytix's Other Stockholders Equity for the quarter that ended in Dec. 2025 was $16.60 Mil.

Renalytix's quarterly Other Stockholders Equity increased from Dec. 2024 ($12.97 Mil) to Jun. 2025 ($15.70 Mil) and increased from Jun. 2025 ($15.70 Mil) to Dec. 2025 ($16.60 Mil).

Renalytix's annual Other Stockholders Equity increased from Jun. 2023 ($-1.45 Mil) to Jun. 2024 ($13.40 Mil) and increased from Jun. 2024 ($13.40 Mil) to Jun. 2025 ($15.70 Mil).

Renalytix Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Renalytix's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renalytix Other Stockholders Equity Chart

Renalytix Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Stockholders Equity
Get a 7-Day Free Trial 14.64 -0.92 -1.45 13.40 15.70

Renalytix Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.66 13.40 12.97 15.70 16.60

Renalytix Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of $16.60 Mil mean?
Renalytix (RENXF) has a Other Stockholders Equity of $16.60 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Renalytix and its competitors.
Is Renalytix's Other Stockholders Equity too high?
Renalytix's current Other Stockholders Equity is $16.60 Mil.
How does Renalytix's Other Stockholders Equity compare to VEEV and BTSG?
Renalytix's Other Stockholders Equity of $16.60 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Healthcare Providers & Services company?
A good Other Stockholders Equity depends on the Healthcare Providers & Services industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Renalytix and its competitors. Renalytix's current Other Stockholders Equity is $16.60 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renalytix stock overvalued right now?
Based on GuruFocus' analysis, Renalytix (RENXF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.06, compared to a current price of $0.04 — trading 39.8% below its estimated fair value. The current Other Stockholders Equity is $16.60 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Renalytix (RENXF), the current Other Stockholders Equity is $16.60 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Renalytix Business Description

Other Exchanges RENX:UK2O9:Germany
Address 2 Leman Street, London, GBR, E1W 9US
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.